CCL2 and chronic kidney disease: Accordingly, macrophage/monocyte cell lines treated with serum of CKD patients have increased expression of the metabolic activation markers CD36, PLIN2, and ABCA1 and they also produce higher levels of inflammatory cytokines and CCL2 compared with exposure to serum from control patients [26].